Previous research showed that MASLD leads to the downregulation of hepatic SIRT1, PGC-1α, CPT1α, and PPARα expression, and SIRT1 deficiency impairs PPARα signaling and fatty acid oxidation [52–56]. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.